BSE Live
Sep 30, 16:01Prev. Close
1958.85
Open Price
1958.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 30, 15:52Prev. Close
1958.20
Open Price
1965.90
Bid Price (Qty.)
1952.70 (890)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Glenmark Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 9,010.54 | 7,649.76 | 8,019.67 | 8,017.38 | 7,450.91 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 9,010.54 | 7,649.76 | 8,019.67 | 8,017.38 | 7,450.91 | |
Total Operating Revenues | 9,226.41 | 7,891.12 | 8,220.66 | 8,141.58 | 7,567.93 | |
Other Income | 356.37 | 1,168.02 | 985.94 | 614.63 | 396.24 | |
Total Revenue | 9,582.78 | 9,059.14 | 9,206.60 | 8,756.21 | 7,964.17 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 2,781.45 | 2,990.41 | 3,035.88 | 2,993.04 | 2,678.26 | |
Purchase Of Stock-In Trade | 373.21 | 322.78 | 391.19 | 481.62 | 315.96 | |
Operating And Direct Expenses | 48.30 | 47.55 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | 44.48 | -103.07 | -31.37 | -16.13 | 5.24 | |
Employee Benefit Expenses | 1,603.50 | 1,434.78 | 1,346.51 | 1,193.20 | 1,107.40 | |
Finance Costs | 48.73 | 277.11 | 206.82 | 236.04 | 265.90 | |
Depreciation And Amortisation Expenses | 218.63 | 202.16 | 184.15 | 159.70 | 150.82 | |
Other Expenses | 2,131.31 | 1,957.01 | 2,005.68 | 1,801.64 | 1,570.74 | |
Total Expenses | 7,249.59 | 7,128.73 | 7,138.86 | 6,849.10 | 6,094.31 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 2,333.18 | 1,930.42 | 2,067.74 | 1,907.11 | 1,869.87 | |
Exceptional Items | -179.17 | 5,070.33 | -495.87 | 430.33 | 73.89 | |
Profit/Loss Before Tax | 2,154.02 | 7,000.75 | 1,571.87 | 2,337.45 | 1,943.76 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 316.09 | 1,049.99 | 386.93 | 411.08 | 343.62 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | 227.58 | 783.46 | -23.83 | -71.42 | -49.31 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 543.67 | 1,833.46 | 363.11 | 339.66 | 294.31 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 1,610.35 | 5,167.29 | 1,208.77 | 1,997.79 | 1,649.45 | |
Profit/Loss From Continuing Operations | 1,610.35 | 5,167.29 | 1,208.77 | 1,997.79 | 1,649.45 | |
Profit/Loss For The Period | 1,610.35 | 5,167.29 | 1,208.77 | 1,997.79 | 1,649.45 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 57.07 | 183.13 | 42.84 | 70.80 | 58.46 | |
Diluted EPS (Rs.) | 57.07 | 183.13 | 42.84 | 70.80 | 58.46 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 70.55 | 70.54 | 70.54 | 70.54 | 70.54 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 |
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
03.12.2024
Glenmark Consolidated September 2024 Net Sales at Rs 3,433.80 crore, up 7.06% Y-o-Y
20.11.2024
Glenmark Standalone September 2024 Net Sales at Rs 2,636.10 crore, up 18.03% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015